-

Cresco Labs Announces Conference Participation for June 2022

CHICAGO--(BUSINESS WIRE)--Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced its executive team will participate in the following conferences in June 2022:

Jefferies Cannabis Summit, June 2, 2022 (New York): Chief Commercial Officer Greg Butler will participate in a panel titled, “Building a $1 billion Cannabis Brand”, moderated by analyst Owen Bennett and management will participate in one-on-one meetings.

Oppenheimer Consumer Growth and E-Commerce Conference, June 14, 2022 (virtual): Chief Executive Officer Charles Bachtell will participate in a fireside chat moderated by analyst Rupesh Parikh and management will participate in one-on-one meetings.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Facebook: Cresco Labs
Instagram: Cresco Labs
Twitter: Cresco Labs

Contacts

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com

Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

Cresco Labs Inc.

CNSX:CL

Release Summary
CRESCO LABS ANNOUNCES CONFERENCE PARTICIPATION FOR JUNE 2022
Release Versions

Contacts

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com

Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com

More News From Cresco Labs Inc.

Cresco Labs to Report Fourth Quarter 2025 Financial Results on March 5, 2026

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the full year and quarter ended December 31st, 2025 on Thursday, March 5, 2026 before the market opens. The Company will host a conference call and webcast to discuss its financial results and provide...

Cresco Labs Opens Sunnyside Tamarac, Expanding Patient Access in Broward County, Florida

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the grand opening of Sunnyside Tamarac, located at 6001 N University Drive in Tamarac, Fla. It is the Company’s 31st dispensary in Florida and 72nd nationwide. “Florida is the largest medical market in the country, and opening Sunnyside Tamarac reinforces our long-term commitment to serving patients across the state,” said Charlie Bachtell, CEO of Cresco Labs. “We’re...

Cresco Labs CEO: Rescheduling Marks Historic Shift for Cannabis Industry

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump’s action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act. “Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, ackn...
Back to Newsroom